A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)

Inclusion Criteria: * Females of couples with an indication for controlled ovarian stimulation (COS) and IVF or ICSI that have had at least one previous COS cycle with proven normal ovarian response; * \>=18 and \<= 39 years of age at the time of signing informed consent; * a. First group: Body weight \>= 50 kg and BMI \>= 18 and \<= 29 kg/m\^2; b. Second group: Body weight \<= 60 kg and BMI \<= 29 kg/m\^2; * Normal menstrual cycle length: 24-35 days; * Ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed); * Normal routine diagnostic hysteroscopy and endometrial biopsy; * Willing and able to sign informed consent. Exclusion Criteria: * History of or any current (treated) endocrine abnormality; * History of ovarian hyper-response1 or history of ovarian hyperstimulation syndrome (OHSS); * History of or current polycystic ovary syndrome (PCOS); * A basal antral follicle count \> 20 (size \< 11 mm, both ovaries combined) on USS during the early follicular phase (menstrual cycle day 2-5); * Less than 2 ovaries or any other ovarian abnormality; * Presence of unilateral or bilateral hydrosalpinx (visible on USS); * Presence of unilateral or bilateral endometriomas (\>10 mm; visible on USS); * More than three unsuccessful COS cycles since the last established ongoing pregnancy (if applicable); * History of non- or low ovarian response to FSH/hMG treatment; * FSH or LH \> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5); * Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase; * Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) or GnRH analogues (e.g. hypersensitivity, pregnancy/lactation); * Recent history of or current epilepsy, diabetes or cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease; * History or presence of alcohol or drug abuse within 12 months prior to signing informed consent; * Previous use of Org 36286; * Use of hormonal preparations within 1 month prior to screening; * Administration of investigational drugs within three months prior to signing informed consent.